C018 – Experimental Neurology of Parkinson´s Disease

Objectives and lines of research


During the last 15 years our activity has been focused on studying the mechanisms responsible for the degeneration of dopaminergic neurons and the development of new therapeutic strategies.

The study is approached from several lines of research:

• Neuroprotection of dopaminergic neurons

• Role of the cerebral Renin Angiotensin System in dopaminergic degeneration.

• In vitro generation of dopaminergic neurons from neural stem cells or induced pluripotent stem cells (iPs) to drive cell therapy in Parkinson’s disease.

• Pharmacological approach to dyskinesias.

• Search for biomarkers of onset and progression of Parkinson’s Disease.

Lines of research

• Development of neuroprotection strategies in in vivo and in vitro models of dopaminergic degeneration.
• Development of methods for the proliferation and differentiation of dopaminergic neurons from stem cells or neural stem cells for cell therapy in animal models of Parkinson’s disease.
• Pharmacological approach to dyskinesias.
• Search for biomarkers of onset/progression of Parkinson’s disease.


Research team
Labandeira García, José Luis

Researchers (established or associate)
Diaz Ruiz, María Carmen
Domínguez Meijide, Antonio
Garrido Gil, Pablo
Guerra Seijas, María Josefa
Muñoz Patiño, Ana María
Parga Martín, Juan Andrés
Rodríguez Pallares, Jannette
Rodríguez Pérez, Ana Isabel
Suárez Quintanilla, Juan Antonio.
Valenzuela Limiñana, Rita
Villar Cheda, Mª Begoña

Postdoctoral researchers
Costa Besada, Mª Alicia
García Garrote, María
López López, Andrea

Predoctoral researcher
Labandeira Guerra, Carmen María
Lage Pita, Lucía
Pedrosa Sánchez, Mª Ángeles
Quijano Ocampo, Aloia


Technical support staff
Aldrey García, Pilar
Gianzo Quintela, Cristina
Novoa Pérez, Mª Iria

  • Garcia-Garrote, M., Parga, J. A., Labandeira, P. J., Labandeira-Garcia, J. L., & Rodriguez-Pallares, J. (2021). Dopamine regulates adult neurogenesis in the ventricular-subventricular zone via dopamine D3 angiotensin type 2 receptor interactions. Stem Cells, 39(12), 1778-1794. doi:10.1002/stem.3457
  • Valenzuela, R., Rodriguez-Perez, A. I., Costa-Besada, M. A., Rivas-Santisteban, R., Garrido-Gil, P., Lopez-Lopez, A., Navarro, G., Lanciego, J. L., Franco, R., & Labandeira-Garcia, J. L. (2021). An ACE2/Mas-related receptor MrgE axis in dopaminergic neuron mitochondria. Redox Biol, 46, 102078. doi:10.1016/j.redox.2021.102078
  • Rodriguez-Perez, A. I., Labandeira, C. M., Pedrosa, M. A., Valenzuela, R., Suarez-Quintanilla, J. A., Cortes-Ayaso, M., Mayan-Conesa, P., & Labandeira-Garcia, J. L. (2021). Autoantibodies against ACE2 and angiotensin type-1 receptors increase severity of COVID-19. J Autoimmun, 122, 102683. doi:10.1016/j.jaut.2021.102683
  • Valenzuela, R., Pedrosa, M. A., Garrido-Gil, P., Labandeira, C. M., Navarro, G., Franco, R., Rodriguez-Perez, A. I., & Labandeira-Garcia, J. L. (2021). Interactions between ibuprofen, ACE2, renin-angiotensin system, and spike protein in the lung. Implications for COVID-19. Clin Transl Med, 11(4), e371. doi:10.1002/ctm2.371
  • Pedrosa, M. A., Valenzuela, R., Garrido-Gil, P., Labandeira, C. M., Navarro, G., Franco, R., Labandeira-Garcia, J. L., & Rodriguez-Perez, A. I. (2021). Experimental data using candesartan and captopril indicate no double-edged sword effect in COVID-19. Clin Sci (Lond), 135(3), 465-481. doi:10.1042/CS20201511
  • Lopez-Lopez, A., Labandeira, C. M., Labandeira-Garcia, J. L., & Munoz, A. (2020). Rho kinase inhibitor fasudil reduces l-DOPA-induced dyskinesia in a rat model of Parkinson’s disease. Br J Pharmacol, 177(24), 5622-5641. doi:10.1111/bph.15275
  • Rodriguez-Perez, A. I., Garrido-Gil, P., Pedrosa, M. A., Garcia-Garrote, M., Valenzuela, R., Navarro, G., Franco, R., & Labandeira-Garcia, J. L. (2020). Angiotensin type 2 receptors: Role in aging and neuroinflammation in the substantia nigra. Brain Behav Immun, 87, 256-271. doi:10.1016/j.bbi.2019.12.011
  • Seoane-Collazo, P., Linares-Pose, L., Rial-Pensado, E., Romero-Pico, A., Moreno-Navarrete, J. M., Martinez-Sanchez, N., Garrido-Gil, P., Iglesias-Rey, R., Morgan, D. A., Tomasini, N., Malone, S. A., Senra, A., Folgueira, C., Medina-Gomez, G., Sobrino, T., Labandeira-Garcia, J. L., Nogueiras, R., Domingos, A. I., Fernandez-Real, J. M., Rahmouni, K., Dieguez, C., & Lopez, M. (2019). Central nicotine induces browning through hypothalamic kappa opioid receptor. Nat Commun, 10(1), 4037. doi:10.1038/s41467-019-12004-z

Lead researcher

José Luis Labandeira García

José Luis Labandeira García